IL2 and lung cancer: In this regard, since 2000, we have conducted studies evaluating the efficacy of a combination treatment approach consisting of weekly chemotherapy with cisplatin and epirubicin with immunotherapy (recombinant IL-2) and anti-inflammatory (medroxyprogesterone acetate) and antioxidant agents in patients with advanced (stage IIIB-IV) lung cancer with cancer-related anorexia and cachexia [111].